Twist Bioscience (NASDAQ:TWST) SVP Sells $43,412.05 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 935 shares of the stock in a transaction on Friday, March 6th. The shares were sold at an average price of $46.43, for a total value of $43,412.05. Following the completion of the sale, the senior vice president owned 124,401 shares of the company’s stock, valued at $5,775,938.43. The trade was a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Paula Green also recently made the following trade(s):

• On Tuesday, February 3rd, Paula Green sold 1,194 shares of Twist Bioscience stock. The stock was sold at an average price of $46.58, for a total value of $55,616.52.
• On Monday, December 22nd, Paula Green sold 273 shares of Twist Bioscience stock. The shares were sold at an average price of $34.56, for a total value of $9,434.88.

Twist Bioscience Trading Up 1.5%

Shares of TWST stock traded up $0.63 on Friday, hitting $43.65. The company had a trading volume of 73,532 shares, compared to its average volume of 1,340,384. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $57.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. The firm has a market cap of $2.68 billion, a P/E ratio of -34.14 and a beta of 2.23. The stock’s 50-day moving average is $44.72 and its two-hundred day moving average is $35.06.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The company had revenue of $103.70 million during the quarter, compared to analyst estimates of $100.32 million. The firm’s quarterly revenue was up 16.9% compared to the same quarter last year. On average, equities research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Quarry LP bought a new stake in Twist Bioscience in the third quarter valued at $28,000. Smartleaf Asset Management LLC boosted its position in shares of Twist Bioscience by 70.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after purchasing an additional 442 shares in the last quarter. Strategic Advocates LLC grew its stake in shares of Twist Bioscience by 562.7% in the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after buying an additional 906 shares during the period. SBI Securities Co. Ltd. increased its position in Twist Bioscience by 68.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after buying an additional 571 shares in the last quarter. Finally, National Bank of Canada FI bought a new stake in Twist Bioscience in the 3rd quarter valued at about $46,000.

Wall Street Analyst Weigh In

TWST has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Evercore boosted their target price on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Barclays boosted their price objective on Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, February 3rd. Finally, Robert W. Baird set a $50.00 target price on Twist Bioscience in a research report on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $45.88.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.